Regeneron Pharmaceuticals Inc

詳細情報 Regeneron Pharmaceuticals Inc 企業名

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

企業情報

企業コードREGN

会社名Regeneron Pharmaceuticals Inc

上場日Apr 02, 1991

最高経営責任者「CEO」Dr. Leonard S. Schleifer, M.D., Ph.D

従業員数15106

証券種類Ordinary Share

決算期末Apr 02

本社所在地777 Old Saw Mill River Road

都市TARRYTOWN

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号10591

電話番号17813705000

ウェブサイトhttps://www.regeneron.com/

企業コードREGN

上場日Apr 02, 1991

最高経営責任者「CEO」Dr. Leonard S. Schleifer, M.D., Ph.D

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

他の

266.30M

8.79%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

他の

266.30M

8.79%

株主

更新時刻: Sat, Aug 30

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

他の

74.12%

株主統計

比率

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

他の

74.12%

種類

株主統計

比率

Investment Advisor

47.70%

Investment Advisor/Hedge Fund

28.50%

Hedge Fund

5.34%

Research Firm

2.70%

Pension Fund

2.54%

Bank and Trust

2.15%

Individual Investor

2.01%

Sovereign Wealth Fund

1.22%

Insurance Company

0.08%

他の

7.75%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

9.36M

8.81%

+117.55K

+1.27%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.74M

5.41%

+45.93K

+0.81%

Mar 31, 2025

State Street Global Advisors (US)

4.79M

4.51%

-42.58K

-0.88%

Mar 31, 2025

Dodge & Cox

2.32M

2.19%

+2.77K

+0.12%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.40M

6.97%

-573.19K

-7.19%

Mar 31, 2025

Capital International Investors

3.99M

3.76%

-747.80K

-15.79%

Mar 31, 2025

JP Morgan Asset Management

4.08M

3.84%

-1.16M

-22.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.47M

2.33%

+41.95K

+1.73%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

2.19M

2.07%

-36.81K

-1.65%

Jun 30, 2025

Putnam Investment Management, L.L.C.

1.91M

1.8%

+285.04K

+17.50%

Mar 31, 2025

詳細を見る

563.900USD

Regeneron Pharmaceuticals Inc

563.900

概要

企業名

金融

分析